Roche CT-388 Obesity Drug Posts 22.5% Weight Loss
Roche CT-388 Obesity Drug shows up to 22.5% placebo-adjusted weight loss at 48 weeks, as Roche moves into Phase 3 to challenge Lilly and Novo.
GLP-1 Weight Loss Drugs Reshape Obesity Care In South Africa
GLP-1 weight loss drugs like Mounjaro and Wegovy are transforming obesity treatment in SA amid rising health concerns and systemic barriers.
Aspen Targets Mounjaro Expansion in Africa Following Approval
Aspen's Mounjaro expansion plans promise to enhance diabetes and weight management treatment in Sub-Saharan Africa soon.
Aspen Boosted by Mounjaro: A New Era in Weight Loss
Aspen shares soar following the approval of Mounjaro for weight loss in South Africa. Discover the impact on obesity management.